7/103 sources · 3 publishersUpdated Oct 20, 17:41 UTC
Goldman Sachs lifts Eli Lilly price target to $1,413, stock rallies
Goldman Sachs raised its target price for Eli Lilly to $1,413, up from $1,371, and kept a Buy rating. The note sparked a 4.6% jump in the shares, sending the stock to a new record high. The same day Metis TechBio disclosed a delivery agreement with Lilly valued at up to $1.1 billion. Analysts also noted the upcoming third‑quarter earnings release on October 29.
Why it matters
The higher target suggests Goldman sees further upside, which could attract additional buying pressure. Investors will watch the Q3 results on October 29 for confirmation of the growth expectations that underpin the new target.
Key facts
- 1Goldman Sachs increased its price target for Eli Lilly to $1,413, up from $1,371. marketscreener.com
- 2Lilly’s shares rose about 4.6% to roughly $1,296 after the target lift. finance.yahoo.com
- 3The stock reached a record level above $1,311 during the session. stocktwits.com
- 4Metis TechBio announced a delivery deal with Lilly worth up to $1.1 billion. marketscreener.com
- 5Analysts project Lilly’s revenue for the current year at $88.5 billion. finance.yahoo.com
- 6Lilly is scheduled to report its third‑quarter 2026 results on October 29. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.